As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Of course, weight loss supplements shouldn't be the first port of call and, before choosing to start taking any of them, it's ...

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are mathematical calculations, so they don’t necessarily represent what’s typical or ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

Mark Millich, 26 years old and insecure about his thinning hair, was curious about the ads he saw promising to reverse his hair loss. He completed a 14-question intake on Hims.com and received a ...

Some companies, like Zealand Pharma and Roche (RHHBY), are developing next-generation treatments with stronger weight-loss effects. Others, like Hims & Hers (HIMS), betted on more affordable off ...

In a note out on TheFly.com today, Bank of America analyst Allen Lutz commented that the "lion's share" of analysts predict that $725 million in weight-loss revenue for Hims & Hers this year will ...

The season ended for the University of Wisconsin men's hockey team Sunday when it couldn't find a ... His goal celebration included removing an imaginary weight from his back. He missed an empty net ...